Belgian biotech firm signs US cancer test deal

Belgian biotech company MDxHealth has signed a deal with U.S. healthcare network Stratose, which will give its prostate cancer testing product access to one of the largest networks in the United States, reports Reuters’ Robert-Jan Bartunek. MDxHealth said this morning that with the signature of the Stratose agreement 80 million people in the United States will now have access to its prostate cancer test. The test provides urologists with actionable information on the decision for repeat biopsy, aiding in the stratification of patients at sufficiently low risk who may avoid repeat biopsy and return to screening, from those who may be at increased risk of harbouring undetected cancers.